Table 1.
In Vitro Activity of WCK 771 Against Staphylococcus aureus (QSSA, QRSA, VISA) Isolates
| Quinolone | S. aureus (MICs in mg/L) | |||||||
|---|---|---|---|---|---|---|---|---|
| All Isolates (N=116) | QSSA (N=44) | QRSA (N=53) | VISA (N=3) | |||||
| MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | |
| WCK 771 | 0.5 | 1 | ≤0.008 | 0.015 | 0.5 | 1 | 1 | 1 |
| Levofloxacin | 4 | 32 | 0.12 | 0.25 | 8 | 32 | 8 | 16 |
| Ciprofloxacin | 16 | >32 | 0.25 | 0.5 | >32 | >32 | 32 | 32 |
| Moxifloxacin | 2 | >4 | 0.03 | 0.06 | 4 | >4 | 4 | 4 |
| Clinafloxacin | 0.25 | 2 | 0.015 | 0.03 | 1 | 2 | 1 | 1 |
Note: Data From: Jacobs MR, Bajaksouzian S, Windau A, et al. In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob Agents Chemother. 2004;48(9):3338–3342.16
Abbreviations: QSSA, quinolone-susceptible S. aureus; QRSA, quinolone-resistant S. aureus; VISA, vancomycin-intermediate S. aureus.